Alvotech (ALVO)
NASDAQ:ALVO
ALVO Stock Chart & Stats
$3.65
$0.06(0.46%)
At close: 4:00 PM EST
$3.65
$0.06(0.46%)
Day’s Range― - ―
52-Week Range$3.03 - $11.85
Previous CloseN/A
Volume41.59K
Average Volume (3M)706.78K
Market Cap
$1.21B
Enterprise Value$2.41B
Total Cash (Recent Filing)$172.36M
Total Debt (Recent Filing)$1.45B
Price to Earnings (P/E)―
Beta1.00
Next Earnings
May 06, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding330,284,150
10 Day Avg. Volume726,778
30 Day Avg. Volume706,782
Financial Highlights & Ratios
PEG Ratio-0.46
Price to Book (P/B)-5.03
Price to Sales (P/S)2.44
P/FCF Ratio-12.49
Enterprise Value/Market Cap2.00
Enterprise Value/Revenue4.12
Enterprise Value/Gross Profit6.88
Enterprise Value/Ebitda30.87
Forecast
1Y Price Target
$4.67Price Target Upside27.95% Upside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)0.09
Revenue Forecast (FY)$634.45M
Bulls Say, Bears Say
Bulls Say
Large, Advancing Biosimilars PipelineA broad 30-product biosimilars pipeline provides durable revenue optionality across multiple therapeutic areas. Over 2–6 months this supports sustained product launches, licensing milestones and partner deals, reducing single-product dependence and enabling multi-year commercial scale if approvals proceed.
Expanded Manufacturing And R&D CapabilitiesInvestments in manufacturing, downstream capacity and R&D teams increase in‑house scale and technical control, improving ability to support simultaneous launches and meet quality standards. This structural capability reduces reliance on third parties and supports margin durability as volumes grow.
Global Partnerships And Commercial LaunchesStrategic deals (e.g., Sandoz supply/commercialization) and multiple global launches broaden market access and de‑risk go‑to‑market execution. Partner-led commercialization accelerates regulatory filings, local market penetration and milestone revenues, enabling more predictable medium‑term revenue streams.
Bears Say
Weak Balance Sheet And Rising DebtElevated and increasing debt with negative shareholders' equity materially constrains financial flexibility. Over the medium term this raises refinancing, covenant and interest‑cost risks, limiting capacity to fund launches or remediate issues without dilutive or costly capital solutions.
Persistent Negative Cash GenerationRepeated negative operating and free cash flow implies ongoing external funding needs. Structural cash burn and inventory builds tie up working capital, increasing dependence on capital markets and raising execution risk for funding multi‑product launches and manufacturing scale‑up.
Material U.S. Regulatory RiskComplete response and post‑action letters for multiple U.S. BLAs create durable timing and revenue risk in the U.S., a critical market. Resubmissions, demonstrated sustained corrective effectiveness and potential follow‑up inspections can delay high‑value launches and compress expected medium‑term cash flows.
Alvotech News
ALVO FAQ
What was Alvotech’s price range in the past 12 months?
Alvotech lowest stock price was $3.03 and its highest was $11.85 in the past 12 months.
What is Alvotech’s market cap?
Alvotech’s market cap is $1.21B.
When is Alvotech’s upcoming earnings report date?
Alvotech’s upcoming earnings report date is May 06, 2026 which is in 32 days.
How were Alvotech’s earnings last quarter?
Alvotech released its earnings results on Mar 18, 2026. The company reported $0.006 earnings per share for the quarter, beating the consensus estimate of -$0.006 by $0.012.
Is Alvotech overvalued?
According to Wall Street analysts Alvotech’s price is currently Undervalued.
Does Alvotech pay dividends?
Alvotech does not currently pay dividends.
What is Alvotech’s EPS estimate?
Alvotech’s EPS estimate is -0.01.
How many shares outstanding does Alvotech have?
Alvotech has 330,284,150 shares outstanding.
What happened to Alvotech’s price movement after its last earnings report?
Alvotech reported an EPS of $0.006 in its last earnings report, beating expectations of -$0.006. Following the earnings report the stock price went down -5.789%.
Which hedge fund is a major shareholder of Alvotech?
Currently, no hedge funds are holding shares in ALVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alvotech Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.67 (27.95% Upside)
$4.67 (27.95% Upside)
Blogger Sentiment
Bullish
ALVO Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 124.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.44%
12-Months-Change
Fundamentals
Return on Equity
-11.92%
Trailing 12-Months
Asset Growth
21.75%
Trailing 12-Months
Company Description
Alvotech
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.
ALVO Company Deck
ALVO Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mix of strong commercial and financial progress—21% revenue growth, 27% EBITDA growth, broadened partnerships, multiple non-U.S. approvals/launches, a large 30-product pipeline and successful capital raises—tempered by a material regulatory setback in the U.S. (CRLs/PAAL tied to an FDA inspection) that requires resubmission and increases near-term timing risk for U.S. revenue. Product-margin pressures, quarter volatility in cash flow, elevated borrowings and balance-sheet adjustments also add short-term risk. Management outlined concrete remediation steps, dual-sourcing initiatives, and clear operational priorities, which mitigate but do not eliminate near-term execution and timing uncertainty.View all ALVO earnings summariesALVO Stock 12 Month Forecast
Average Price Target
$4.67
▲(27.95% Upside)
Technical Analysis
Perrigo Company
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
HUTCHMED
―
Amneal Pharmaceuticals
―
Ownership Overview
―
Insiders
1.56% Mutual Funds
2.08% Other Institutional Investors
95.82% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---